pembrolizumab
merck
['kn-189', 'kn-407']
5y updated results of kn-189 (non-squamous) and kn-407 (squamous). os benefit maintained and around 20% alive at 5y. #esmo2022 
Head of pulmonology unit @pneumo_LS @CHUdeLyon
Professor of Pulmonology @UnivLyon1
Scientific head @URCOT_lyon & @IFCTlung
#liquidbiopsy~#screening~????